Sjögren's Syndrome Market to Witness Sustained Growth During the Forecast Period (2026-2036) Due to the Development of Targeted Immunotherapies, FcRn Inhibitors, TYK2 Inhibitors, and Cell Therapies | DelveInsight

TelitaciceptDazodalibepNipocalimabPositive

AI Analysis

Summary

Market analysis report highlights the Sjögren's syndrome market transformation toward targeted immunomodulatory therapies, including emerging candidates from Vor Biopharma, Amgen, and Johnson & Johnson.

Importance:3/10

Sentiment:

0.30

Sjögren's syndromeimmunotherapiesFcRn inhibitorsTYK2 inhibitorscell therapiesmarket analysis

Related Companies

$AMGN $JNJ

Read the original article

Published by PR Newswire Pharma on September 16, 2026 2:31 PM

Read Original